Syndax Pharmaceuticals (SNDX) Projected to Announce Quarterly Earnings on Monday

Syndax Pharmaceuticals (NASDAQ:SNDX) is projected to announce its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect the company to post earnings of ($0.4928) per share and revenue of $81.80 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, November 2, 2026 at 4:30 PM ET.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.10). The firm had revenue of $72.79 million during the quarter, compared to analysts’ expectations of $79.36 million. Syndax Pharmaceuticals had a negative net margin of 87.52% and a negative return on equity of 372.94%. The business’s quarterly revenue was up 91.8% on a year-over-year basis. During the same period last year, the company earned ($0.83) EPS. On average, analysts expect Syndax Pharmaceuticals to post ($2.01) EPS for the current fiscal year and ($1.01) EPS for the next fiscal year.

Syndax Pharmaceuticals Trading Down 3.5%

Shares of SNDX stock opened at $13.65 on Friday. Syndax Pharmaceuticals has a 1-year low of $12.80 and a 1-year high of $25.59. The company has a debt-to-equity ratio of 38.95, a current ratio of 6.77 and a quick ratio of 6.44. The company has a 50-day moving average of $17.18 and a two-hundred day moving average of $20.25. The firm has a market cap of $1.21 billion, a PE ratio of -5.44 and a beta of 0.42.

Insiders Place Their Bets

In other Syndax Pharmaceuticals news, Director Dennis Podlesak sold 8,000 shares of Syndax Pharmaceuticals stock in a transaction dated Thursday, October 29th. The shares were sold at an average price of $14.21, for a total transaction of $113,680.00. Following the completion of the transaction, the director owned 239,763 shares in the company, valued at approximately $3,407,032.23. The trade was a 3.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 4.80% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the company. HC Wainwright reissued a “buy” rating and set a $38.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, October 13th. Bank of America reaffirmed a “buy” rating on shares of Syndax Pharmaceuticals in a research report on Wednesday, August 5th. Jefferies Financial Group reaffirmed a “buy” rating and set a $35.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday, September 29th. JPMorgan Chase & Co. reduced their target price on shares of Syndax Pharmaceuticals from $44.00 to $40.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Finally, Weiss Ratings downgraded Syndax Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, October 19th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $41.80.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc (NASDAQ:SNDX) is a biopharmaceutical company focused on developing and commercializing therapies for cancer and immune-related diseases. Founded in 2005 and headquartered in Waltham, Massachusetts, the company develops medicines designed to address genetically defined cancers and serious complications associated with cancer treatment.

Syndax’s lead product is Revuforj (revumenib), an oral menin inhibitor approved in the United States for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in eligible adults and children.